We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Events

ATTENTION: Due to the CORONAVIRUS EPIDEMIC, certain events are being rescheduled for a later date or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
14 Apr 2020 - 17 Apr 2020
16 Apr 2020 - 17 Apr 2020

Combining IL-6 Measurement with a Standard Biomarker Panel Improves Diagnosis of Ovarian Cancer

By LabMedica International staff writers
Posted on 26 Feb 2020
Print article
Image: Intermediate magnification micrograph of a low malignant potential (LMP) mucinous ovarian tumor (Photo courtesy of Wikimedia Commons)
Image: Intermediate magnification micrograph of a low malignant potential (LMP) mucinous ovarian tumor (Photo courtesy of Wikimedia Commons)
Addition of the inflammatory biomarker IL-6 (interleukin-6) to a standard panel of tumor markers was found to enchance immunodiagnosis of ovarian cancer.

Ovarian cancer is one of the most common gynaecologic cancers and has the highest mortality rate. About 300,000 new cases are diagnosed each year world wide, with an estimated 60% of patients dying within five years after diagnosis.

Since HGSOC (high-grade serous ovarian cancer) progression is correlated with local and systemic inflammation, investigators at RMIT University (Melbourne, Australia) hypothesised that inclusion of inflammatory biomarkers in sera may improve diagnostic tests.

To test this hypothesis, the investigators used four existing clinical tests (RMI score and ROMA, CA125, and HE4) and a panel of 28 immune soluble biomarkers in sera from 66 patients undergoing surgery for suspected ovarian cancer. For this study, multiplex magnetic bead immunoassay kits were used to simultaneously measure 28 analytes in a single sample. This allowed quantitative measurement of cytokines (GM-CSF, IFN-alpha, IFN-gamma, IL-1beta, IL-1RA, IL-2, IL-2R, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12 (p40/p70), IL-13, IL-15, IL-17 and TNF-alpha) and chemokines (RANTES, Eotaxin, CCL2/MCP-1, CCL3/MIP-1alpha, CCL4/ MIP-1beta, CXCL9/MIG, CXCL10/IP-10) in patient’s serum.

Six promising immune biomarkers alone, or in combination with conventional tests, were subsequently analyzed in an independent validation cohort of 69 patients. The cytokine IL-6 was identified as the main driver of variability followed closely by conventional diagnostic tests. Median sera IL-6 was higher in HGSOC patients compared to those with a benign mass or controls with normal ovaries. The combination of IL-6 further improved the overall predictive probability of the conventional tests.

"Our new test is as accurate as the combined results of a standard blood test and ultrasound," said senior author Dr. Magdalena Plebanski, professor of immunology at RMIT University. "This is especially important for women in remote or disadvantaged communities, where under-resourced hospitals may not have access to complex and expensive equipment like ultrasound machines or MRI scanners. It also means patients with benign cysts identified through imaging could potentially be spared unnecessary surgeries. This study looked at women with advanced ovarian cancer, but we hope further research could explore the potential for adding this biomarker to routine diagnostic tests at earlier stages of the disease."

Results of the study were published in the February 10, 20120, online edition of the journal Scientific Reports.

Related Links:
RMIT University


Print article

Channels

Copyright © 2000-2020 Globetech Media. All rights reserved.